{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:12:37Z","timestamp":1784970757487,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alzheimer\u2019s Foundation of America Award","award":["AWD00004772"],"award-info":[{"award-number":["AWD00004772"]}]},{"name":"Alzheimer\u2019s Foundation of America Award","award":["P01AG060882"],"award-info":[{"award-number":["P01AG060882"]}]},{"name":"Alzheimer\u2019s Foundation of America Award","award":["P30AG066512"],"award-info":[{"award-number":["P30AG066512"]}]},{"name":"Herb and Evelyn Abrams Family Amyloid Research Fund","award":["AWD00004772"],"award-info":[{"award-number":["AWD00004772"]}]},{"name":"Herb and Evelyn Abrams Family Amyloid Research Fund","award":["P01AG060882"],"award-info":[{"award-number":["P01AG060882"]}]},{"name":"Herb and Evelyn Abrams Family Amyloid Research Fund","award":["P30AG066512"],"award-info":[{"award-number":["P30AG066512"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AWD00004772"],"award-info":[{"award-number":["AWD00004772"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01AG060882"],"award-info":[{"award-number":["P01AG060882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30AG066512"],"award-info":[{"award-number":["P30AG066512"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Nilotinib, a tyrosine kinase inhibitor that targets the Abelson tyrosine kinase (c-Abl) signaling pathway, is FDA-approved to treat chronic myeloid leukemia. Nilotinib has properties indicative of a possible utility in neuroprotection that have prompted exploration of repurposing the drug for the treatment of Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD). AD is a progressive age-related neurodegenerative disorder characterized by the deposition of extracellular amyloid-\u03b2 plaques and intracellular neurofibrillary tangles. It is incurable and affects approximately 50 million patients worldwide. Nilotinib reduces c-Abl phosphorylation, amyloid-\u03b2 levels, and dopaminergic neuron degeneration in preclinical AD models. This study explores the effects of nilotinib on amyloid processing and mitochondrial functioning in the SH-SY5Y human neuroblastoma cell line. SH-SY5Y cells were exposed to nilotinib (1, 5, and 10 \u00b5M). Real-time PCR and immunoblot analysis were performed to quantify the expression of genes pertaining to amyloid-\u03b2 processing and neuronal health. Nilotinib did not significantly change APP, BACE1, or ADAM10 mRNA levels. However, BACE1 protein was significantly increased at 1 \u00b5M, and ADAM10 was increased at 10 \u00b5M nilotinib without affecting APP protein expression. Further, nilotinib treatment did not affect the expression of genes associated with neuronal health and mitochondrial functioning. Taken together, our findings do not support the efficacy of nilotinib treatment for neuroprotection.<\/jats:p>","DOI":"10.3390\/life14101241","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:12:28Z","timestamp":1727665948000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nilotinib as a Prospective Treatment for Alzheimer\u2019s Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis"],"prefix":"10.3390","volume":"14","author":[{"given":"Ankita","family":"Srivastava","sequence":"first","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Renna","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8368-2199","authenticated-orcid":false,"given":"Maryann","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-4296","authenticated-orcid":false,"given":"Thomas","family":"Palaia","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-902X","authenticated-orcid":false,"given":"Aaron","family":"Pinkhasov","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving H.","family":"Gomolin","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-8966","authenticated-orcid":false,"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Cognitive Neurology, Grossman School of Medicine, New York University, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"De Leon","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"additional","affiliation":[{"name":"Department Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"},{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113024","DOI":"10.1016\/j.intimp.2024.113024","article-title":"Hidden role of microglia during neurodegenerative disorders and neurocritical care: A mitochondrial perspective","volume":"142","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrneurol.2009.105","article-title":"Alzheimer disease: Alzheimer disease neuropathology in the oldest old","volume":"5","author":"Kril","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.arr.2015.07.002","article-title":"Slowing the progression of Alzheimer\u2019s disease; what works?","volume":"23","author":"Nelson","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/NRL.0000000000000320","article-title":"Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans","volume":"26","author":"Reiss","year":"2021","journal-title":"Neurologist"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1248\/cpb.c24-00069","article-title":"Anti-Amyloid-Beta Antibodies and Anti-Tau Therapies for Alzheimer\u2019s Disease: Recent Advances and Perspectives","volume":"72","author":"Suzuki","year":"2024","journal-title":"Chem. Pharm. Bull."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3233\/ADR-230037","article-title":"Principles of Design of Clinical Trials for Prevention and Treatment of Alzheimer\u2019s Disease and Aging-Associated Cognitive Decline in the ACH2.0 Perspective: Potential Outcomes, Challenges, and Solutions","volume":"7","author":"Volloch","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-019-0266-z","article-title":"Multikinase Abl\/DDR\/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration","volume":"19","author":"Fowler","year":"2019","journal-title":"Drugs R D"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12974-023-02802-0","article-title":"Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer\u2019s disease","volume":"20","author":"Stevenson","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer\u2019s Disease","volume":"88","author":"Turner","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_12","first-page":"e12044","article-title":"Targeting dementias through cancer kinases inhibition","volume":"6","author":"Fagiani","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Franceschi, R.T., Hallett, S.A., and Ge, C. (2023). Discoidin domain receptors; an ancient family of collagen receptors has major roles in bone development, regeneration and metabolism. Front. Dent. Med., 4.","DOI":"10.3389\/fdmed.2023.1181817"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/hmg\/ddaa177","article-title":"Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases","volume":"29","author":"Fowler","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/17460441.2020.1793755","article-title":"Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer\u2019s disease or should they be looking elsewhere?","volume":"15","author":"Imbimbo","year":"2020","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2011-102025","article-title":"Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain","volume":"25","author":"Schlatterer","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Karuppagounder, S.S., Brahmachari, S., Lee, Y., Dawson, V.L., Dawson, T.M., and Ko, H.S. (2014). The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci. Rep., 4.","DOI":"10.1038\/srep04874"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108025","DOI":"10.1016\/j.intimp.2021.108025","article-title":"Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson\u2019s disease models","volume":"99","author":"Wu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.28858","article-title":"Parkinson\u2019s Disease Modification Through Abl Kinase Inhibition: An Opportunity","volume":"37","author":"Werner","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/mds.28389","article-title":"Long-Term Safety and Clinical Effects of Nilotinib in Parkinson\u2019s Disease","volume":"36","author":"Pagan","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/emmm.201302771","article-title":"Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance","volume":"5","author":"Lonskaya","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/hmg\/ddp258","article-title":"Parkin promotes intracellular Abeta1-42 clearance","volume":"18","author":"Burns","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","article-title":"Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance","volume":"92","author":"Lonskaya","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1326-9-46","article-title":"Tau deletion impairs intracellular beta-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models","volume":"9","author":"Lonskaya","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ali, M., Wani, S.U.D., Dey, T., Sridhar, S.B., and Qadrie, Z.L. (2024). A common molecular and cellular pathway in developing Alzheimer and cancer. Biochem. Biophys. Rep., 37.","DOI":"10.1016\/j.bbrep.2023.101625"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Motaln, H., and Rogelj, B. (2023). The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies. Cells, 12.","DOI":"10.3390\/cells12162041"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3233\/JAD-2009-1062","article-title":"Altered subcellular distribution of c-Abl in Alzheimer\u2019s disease","volume":"17","author":"Jing","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of Synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4103\/1673-5374.350700","article-title":"Nilotinib: From animal-based studies to clinical investigation in Alzheimer\u2019s disease patients","volume":"18","author":"Nobili","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Xie, X., Yuan, P., Kou, L., Chen, X., Li, J., and Li, Y. (2022). Nilotinib in Parkinson\u2019s disease: A systematic review and meta-analysis. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.996217"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E.C., Cutuli, D., Cauzzi, E., Marino, R., and Viscomi, M.T. (2021). Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer\u2019s Disease. Prog. Neurobiol., 202.","DOI":"10.1016\/j.pneurobio.2021.102031"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.14336\/AD.2020.0910","article-title":"Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer\u2019s Disease","volume":"12","author":"Adlimoghaddam","year":"2021","journal-title":"Aging Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Nishioka, H., Tooi, N., Isobe, T., Nakatsuji, N., and Aiba, K. (2016). BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer\u2019s disease models. Sci. Rep., 6.","DOI":"10.1038\/srep33427"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Leon, R., Gutierrez, D.A., Pinto, C., Morales, C., de la Fuente, C., Riquelme, C., Cortes, B.I., Gonzalez-Martin, A., Chamorro, D., and Espinosa, N. (2023). c-Abl tyrosine kinase down-regulation as target for memory improvement in Alzheimer\u2019s disease. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1180987"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Srivastava, A., Johnson, M., Renna, H.A., Sheehan, K.M., Ahmed, S., Palaia, T., Pinkhasov, A., Gomolin, I.H., De Leon, J., and Reiss, A.B. (2023). Therapeutic Potential of P110 Peptide: New Insights into Treatment of Alzheimer\u2019s Disease. Life, 13.","DOI":"10.3390\/life13112156"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of Aducanumab in the Treatment of Alzheimer\u2019s Disease: Challenges and Opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3946320231209839","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (Abeta) monoclonal antibody lecanemab for Alzheimer\u2019s disease: A systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chi, Y., Zhang, Q., and Ma, Y. (2023). Safety and efficacy of lecanemab for Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1169499"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","article-title":"Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer\u2019s disease","volume":"136","author":"Morris","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.3390\/cimb45110540","article-title":"Mitochondrial DNA and Inflammation in Alzheimer\u2019s Disease","volume":"45","author":"Galizzi","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1073\/pnas.0903563106","article-title":"Mitochondrial bioenergetic deficit precedes Alzheimer\u2019s pathology in female mouse model of Alzheimer\u2019s disease","volume":"106","author":"Yao","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.arr.2021.101503","article-title":"Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer\u2019s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies","volume":"72","author":"Song","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.omtn.2020.01.010","article-title":"miRNA-31 Improves Cognition and Abolishes Amyloid-beta Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer\u2019s Disease","volume":"19","author":"Carmona","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Du, W., Lei, C., and Dong, Y. (2021). MicroRNA-149 is downregulated in Alzheimer\u2019s disease and inhibits beta-amyloid accumulation and ameliorates neuronal viability through targeting BACE1. Genet. Mol. Biol., 44.","DOI":"10.1590\/1678-4685-gmb-2020-0064"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI20864","article-title":"A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model","volume":"113","author":"Postina","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1523\/JNEUROSCI.3383-10.2010","article-title":"Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer\u2019s disease transgenic mice","volume":"30","author":"Tampellini","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-016-0110-7","article-title":"Synaptophysin depletion and intraneuronal Abeta in organotypic hippocampal slice cultures from huAPP transgenic mice","volume":"11","author":"Harwell","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2174\/1570159X19666210517114016","article-title":"Mitochondrial Dysfunction in Alzheimer\u2019s Disease: Opportunities for Drug Development","volume":"20","author":"Bhatia","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1111\/bph.14585","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease: Role in pathogenesis and novel therapeutic opportunities","volume":"176","author":"Swerdlow","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2353\/ajpath.2008.071208","article-title":"Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer\u2019s disease patients","volume":"173","author":"Wang","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/exnr.2000.7333","article-title":"Abnormal mitochondrial morphology in sporadic Parkinson\u2019s and Alzheimer\u2019s disease cybrid cell lines","volume":"162","author":"Trimmer","year":"2000","journal-title":"Exp. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbadis.2011.01.007","article-title":"Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer\u2019s disease neurons","volume":"1812","author":"Calkins","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1096\/fj.05-3735fje","article-title":"Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer\u2019s disease","volume":"19","author":"Caspersen","year":"2005","journal-title":"FASEB J."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/10\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:05:49Z","timestamp":1760112349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/10\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["life14101241"],"URL":"https:\/\/doi.org\/10.3390\/life14101241","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}